Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 (HealthDay News) -- For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or
"Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint," Galsky said in a statement. "If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Related Posts
AHA News: Después de una subida en la mortalidad materna para las mujeres hispanas, se buscan respuestas
VIERNES, 30 de septiembre de 2022 (American Heart Association News) -- La...
No Cognitive Benefits Seen for Meditation, Nonnative Language Training
MONDAY, July 24, 2023 (HealthDay News) -- Meditation and nonnative language...
Una agencia de la OMS declara que el aspartamo es un posible carcinógeno
VIERNES, 14 de julio de 2023 (HealthDay News) -- El jueves, una agencia de la...
Respirar aire contaminado aumenta las probabilidades de una amplia variedad de cánceres
MIÉRCOLES, 9 de agosto de 2023 (HealthDay News) -- Una nueva investigación...